This is the protocol for a review and there is no abstract. The objectives are as follows:
To evaluate the clinical effectiveness and safety of octreotide either alone or combined with other agents in the treatment of inoperable malignant bowel obstruction induced by abdominal or pelvic cancers such as gastro-intestinal or gynaecology cancers.
The following comparison will be carried out in this review:
Octreotide compared with placebo or no treatment;
Octreotide compared with other agents;
Octreotide combined with other agents compared with placebo or no treatment;
Octreotide combined with other agents compared with other agents without octreotide;
Studies comparing the different regimens of octreotide will be included.